Want to see TSE:PREV full AI Analyst Report?
PreveCeutical Medical (PREV) AI Stock Analysis
PreveCeutical Medical
(CNQX:PREV)
The overall score is severely depressed by the company's critical financial state: zero revenue, negative equity, and an accelerating cash burn that points to insolvency. The stock's valuation is purely speculative with negative earnings. The only positive factor is a short-term technical uptrend, but this is a fragile signal against a backdrop of fundamental collapse and is contradicted by overbought stochastic readings.
PreveCeutical Medical (PREV) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 9.89M
- Dividend Yield
- ―
- Average Volume (3M)
- 235.58K
- Price to Earnings (P/E)
- -16.7
- Beta (1Y)
- -0.48
- Revenue Growth
- ―
- EPS Growth
- -36.36%
- Country
- Canada
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PreveCeutical Medical Business Overview & Revenue Model
Company Description
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid So...
How the Company Makes Money
PreveCeutical Medical’s ability to generate revenue is primarily tied to commercialization of its product candidates and monetization of its intellectual property, including potential licensing or partnering arrangements for its drug-delivery technol...
PreveCeutical Medical Financial Statement Overview
Summary
The company is pre-revenue with zero sales, deeply negative equity (-$6.7M), and an accelerating cash burn (-$1.6M TTM). It is technically insolvent, surviving only on debt. While net losses have narrowed, the complete lack of revenue and unsustainable financial structure warrant the lowest possible score.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -7,243 | -14.43K | -10.10K | -9,856 | -9,891 | -5,091 |
| EBITDA | -272.46K | -1.35M | -837.46K | -955.09K | -1.23M | -829.83K |
| Net Income | -687.11K | -1.58M | -1,174 | -1.27M | -1.48M | -1.73M |
Balance Sheet | ||||||
| Total Assets | 1.51M | 1.45M | 225.66K | 181.51K | 189.14K | 161.20K |
| Cash, Cash Equivalents and Short-Term Investments | 35.66K | 10.24K | 59.14K | 1,432 | 5,624 | 16.06K |
| Total Debt | 4.84M | 4.68M | 4.46M | 3.89M | 3.23M | 2.93M |
| Total Liabilities | 8.20M | 7.69M | 6.86M | 5.96M | 4.82M | 4.27M |
| Stockholders Equity | -6.69M | -6.24M | -6.64M | -5.78M | -4.64M | -4.10M |
Cash Flow | ||||||
| Free Cash Flow | -1.60M | -1.72M | -428.49K | -296.97K | -222.64K | -481.59K |
| Operating Cash Flow | -1.60M | -1.72M | -426.69K | -296.97K | -222.64K | -426.39K |
| Investing Cash Flow | 57.04K | -2,961 | -1,799 | 0 | 850 | -52.70K |
| Financing Cash Flow | 1.57M | 1.68M | 487.64K | 293.62K | 211.72K | 136.75K |
PreveCeutical Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 53.45 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PREV.
PreveCeutical Medical Peers Comparison
Overall Rating
TSE:MDMA50Neutral- TSE:PREV44Neutral
TSE:BETR41Neutral
TSE:DOSE38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:MDMA | 50Neutral | CAD 18.57M | -12.42 | -72.15% | ― | 224.46% | 28.37% |
| TSE:PREV | 44Neutral | CAD 12.76M | -16.67 | 10.15% | ― | ― | -36.36% |
| TSE:BETR | 41Neutral | CAD 154.50M | -10.91 | 34.90% | ― | ― | -266.67% |
| TSE:DOSE | 38Underperform | CAD 14.33M | -4.68 | 42.51% | ― | -19.31% | 34.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:PREV | PreveCeutical Medical | 0.02 | -0.01 | -33.33% | |
| TSE:DOSE | Rapid Dose Therapeutics Corp | 0.11 | -0.06 | -33.33% | |
| TSE:BETR | Betterlife Pharma Inc. | 0.24 | 0.17 | 242.86% | |
| TSE:MYND | Mynd Life Sciences Inc | 0.07 | 0.00 | 0.00% | |
| TSE:MDMA | PharmAla Biotech Holdings, Inc. | 0.18 | 0.07 | 60.87% |
PreveCeutical Medical Corporate Events
PreveCeutical Raises $156,000 in First Tranche of Private Placement
PositivePreveCeutical Medical has closed the initial tranche of its previously announced $600,000 non-brokered private placement, issuing 5,200,000 units at $0.03 per unit for gross proceeds of $156,000, with each unit consisting of one common share and half...
PreveCeutical Launches $600,000 Private Placement to Fund R&D and Corporate Costs
PositivePreveCeutical Medical Inc. announced a non-brokered private placement of up to 20,000,000 units at $0.03 per unit to raise gross proceeds of up to $600,000, with each unit comprising one common share and half a share purchase warrant. The warrants ar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026